Kengrexal

Cangrelor, the active ingredient in Kengrexal, is a P2Y12 receptor antagonist presented as an injectable solution for intravenous use. It provides rapid, reversible platelet inhibition for patients undergoing percutaneous coronary intervention, helping to reduce periprocedural myocardial infarction and other ischemic complications.

GNH USA supplies Kengrexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Cangrelor is used as an antiplatelet agent in the coronary intervention pathway.

- Percutaneous coronary intervention (PCI): Provides rapid, reversible platelet inhibition to reduce periprocedural myocardial infarction. - Adjunct to aspirin during PCI: Enhances antiplatelet effect when immediate platelet inhibition is required. - High‑risk PCI patients: Helps lower the incidence of ischemic complications during the procedure.

Cangrelor may cause a range of adverse reactions, most of which are related to its antiplatelet activity.

Common Side Effects: - Bleeding at the injection site - Mild bruising or ecchymosis - Hypotension - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Thrombocytopenia - Anaphylactic or severe allergic reactions - Myocardial infarction despite therapy - Stroke or transient ischemic attack

When using Kengrexal, clinicians should observe several safety measures.

- Assess bleeding risk: Review patient history for recent hemorrhage or coagulopathy. - Monitor platelet function: Perform laboratory checks during and after infusion. - Avoid in active severe bleeding: Contraindicated in patients with uncontrolled hemorrhage. - Use with caution in hepatic impairment: Adjust monitoring as liver disease may affect metabolism. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Cangrelor can interact with other agents that affect hemostasis.

Major Interactions (Avoid): - Concurrent use with other potent antiplatelet agents (e.g., clopidogrel, ticagrelor): may cause uncontrolled bleeding. - Combination with anticoagulants (e.g., heparin, warfarin) without monitoring: increased bleeding risk. - Use with glycoprotein IIb/IIIa inhibitors: additive antiplatelet effect leading to severe hemorrhage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase bleeding tendency. - Selective serotonin reuptake inhibitors (SSRIs): potential for enhanced bleeding. - Proton pump inhibitors: generally safe but monitor for gastrointestinal bleeding.